

**SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF NOVEL BISARYLAMINO
THIAZOLOYL BENZOTHAZOLES**

B. Jini Kumari and T. F. Abbs Fen Reji*

Department of Chemistry and Research Centre, Nesamony Memorial Christian College, Marthandam-629165, Tamilnadu, India.

*Correspondence for Author: T. F. Abbs Fen Reji

Department of Chemistry & Research Centre, Nesamony Memorial Christian College, Marthandam-629165, Tamilnadu, India.

Article Received on 20/11/2015

Article Revised on 12/12/2015

Article Accepted on 01/01/2016

ABSTRACT


A series of 2-[2,4-bis(aryl/alkylamino)thiazol-5-oyl]benzothiazole derivatives were synthesized from 1-aryl-3-(N,N'-diarylamidino)thioureas and 2-(2-bromoacetyl)benzothiazole with triethylamine. Their structures were established on the basis of IR, ¹H NMR, ¹³C NMR and mass spectral analyses. All the synthesized compounds were screened for their antibacterial and antifungal potential. All the compounds showed significant activity against the microorganisms tested.

KEYWORDS: Benzothiazoles, Antibacterial activity; Antifungal activity; Triethylamine.

1. INTRODUCTION

It is well-known fact that infectious microorganisms, i.e. bacteria and fungi, cause serious diseases and responsible for nearly one-half of the deaths in india. Marine Organisms are known to contain several pharmacologically active compounds. A few marine natural products or their synthetic analogs are in clinical use or at various stages of drug development. Many alkaloids are derived from marine organisms such as sponges, coelenterates, tunicates (ascuiduians), bryosoans, red algae and symbiotic bacteria. Many of them have been reported to have antitumor (Aiello et al;

2008), antimicrobial (sareen et al; 2006), antileishmaial (Delmas et al;2004), anticonvulsant (Ugale et al;2012), antidiabetic (pattan et al;2005), and anti-inflammatory (Venkatesh and pandeya, 2009) activities. In the light of literature survey, these compounds possess benzothiazole unit having a useful pharmacophore moiety and exhibit anti-cancer, anti-inflammatory, anti-bacterial, anti fungal, anti-tubercular, and anti oxidant activities. For this study we have prepared novel derivatives of bisarylaminothiazoloylbenzothiazoles **3 a-i** (**Table 3**). All the synthesized compounds were screened for their antibacterial and anti fungal activities.



2. Experimental

2.1. MATERIAL AND METHODS

The reagents and solvents used were of AR grade. All chemicals were purchased from merck specialties pvt. Ltd. and Himedia Laboratories pvt. Ltd. The spectra were recorded on JEOL DRX 300 or DPX 300 NMR spectrometer (300 MHz for ¹H and 75 MHz for ¹³C NMR spectra), JEOL SX 102/DA-6000 mass spectrometer (using argon/ xenon, 6 kV, Ma as the FAB gas and m-nitro-benzyl alcohol as the matrix) for FAB mass spectra and Nicolet 400D FTIR spectrometer. Melting points

were uncorrected. Elemental analysis was done at the Central Drug Research Institute, India.

2.2. General procedure for the synthesis of 2-[2,4-bis(arylamino)thiazol-5-oyl]benzothiazoles 3a-i

The reaction sequences employed for the synthesis of title compounds are shown in scheme 1. 2-[2,4-bis(arylamino)thiazol-5-oyl]benzothiazoles **3a-i** were prepared according to the following method (Abbs Fen Reji et al., 2009). A solution of 1-aryl-3-(N,N'-

diarylamidino)thiourea (1 mmol) in DMF (2ml) was added to a solution of 2-(2-bromoacetyl)benzothiazole **2** (0.254g, 1m mol), which was prepared from 2-(1-hydroxyethyl)benzothiazole (Sawhney and singh, 1970; Gupta et al, 1980; Joshua and Rajasekharan, 1974; Hunter, 1925a,b, 1926) in DMF (2ml) . The reaction mixture was stirred well and triethylamine (0.15 ml, 1mmol) was added .The reaction mixture was warmed at 35-40°C for 10min. It was then cooled and poured into ice-cold water with constant stirring. A yellowish orange precipitate thus obtained was filtered, washed with water and dried. The crude product was crystallized from methanol: water (2:1) and then from benzene: petroleum ether (1:1) to give a yellowish orange crystalline solid.

2.3. 2-[2,4-bis(4-chlorophenylamino)thiazol-5-oyl]benzothiazole **3a**

This was prepared and purified as per the above mentioned procedure. Yield 65% , m.p. 258-59°C Analysis: Found: C,55.69; H, 2.99; N, 11.41%; Calc. for $C_{17}H_{12}N_4OS_2$ (252.43): C55.53; H, 2.84; N, 11.26%; IR(KBr) cm^{-1} : 3428,3275,3207,3066, 1631, 1572,1497, 1424, 1269, 1221, 1186, 1095, 1021, 928, 826, 756, 628; 1H NMR: (300 MHz, DMSO-d₆) δ 7.41-7.79 (m, 10H,H-5, H-6, 8ArH), 8.08 (d, 9 Hz, 1H, H-4); 8.20 (d, 9 Hz,1H, H-7), 11.76 (s, 1H, NH) . ^{13}C NMR; (75 MHz, DMSO-d₆) δ ; 21.68, 21.72, 96.25, 114.08, 114.43, 115.00, 121.92, 122.23, 123.80, 128.49, 132.88, 136.63, 136.72, 151.64, 156.29, 169.24, 169.98; FABMS: 497(MH⁺).

2.4. 2-(2-phenylamino-4-chlorophenylaminothiazol-5-oyl)benzothiazole **3b**

This was prepared and purified as per the above mentioned procedure. Yield 70% , m.p. 204°C Analysis: Found: C,59.645; H, 3.241; N, 12.121%; Calc. for $C_{23}H_{15}ClN_4OS_2$ (463.01): C,59.664; H, 3.272; N, 12.103%; IR(KBr) cm^{-1} :3671, 3311, 3065, 3056, 2357, 1629, 1481, 1194, 506; 1H NMR: (300MHz, CdCl₃) δ ; 8.251(s, 1H); 7.440-7.207 (m, 10 H); 7.957 (s, 1H) .

2.5. 2-(2-methylamino-4-chlorophenylaminothiazol-5-oyl)benzothiazole **3c**

This was prepared and purified as per the above mentioned procedure. Yield 70% , m.p. 226.27°C Analysis:Found:C,52.453;H,3.321;N,14.123%;Calc.for $C_{17}H_{13}ClN_4OS_2$ (388.92):C52.500;H,3.315;N,14.408%;IR(KBr) cm^{-1} :3297, 2862, 2918, 1645, 1617, 1519, 1561, 1411, 1377, 1310, 1238, 1115, 1051, 908, 847 , 819, 786, 758 ; 1H NMR: (300MHz, CdCl₃) δ ; 7.234 (t, J= 8.4 Hz, 7 H); 2.400-2.300 (m, 2H); 1.245 (s, 1H) .

2.6. 2-(2-methoxyamino-4-chlorophenylaminothiazol-5-oyl)benzothiazole **3d**

This was prepared and purified as per the above mentioned procedure. Yield 65% , m.p. 199.201°C Analysis: Found: C,49.612; H, 3.123; N, 13.564%; Calc. for $C_{17}H_{13}ClN_4O_2S_2$ (409.92): C49.810;H,3.203;N, 13.670%;IR(KBr) cm^{-1} :3424, 312, 2358, 1617, 1562, 1490, 1401, 1211, 1081, 1020, 819, 756, 724, 501; 1H

NMR: (300MHz, CdCl₃) δ : 7.2307 (t, J= 7.95 Hz, 2 H); 7.139 (d, J= 6 Hz, 2 H); 6.367 (s, 1H); 3.325 (s, 3 H) .

2.7. 2-(2-ethoxyamino-4-chlorophenylaminothiazol-5-oyl)benzothiazole **3e**

This was prepared and purified as per the above mentioned procedure. Yield 69% , m.p. 223°C Analysis: Found: C,51.564; H, 3.321; N, 13.232%; Calc. for $C_{18}H_{15}ClN_4O_2S_2$ (418.95): C51.607; H, 3.6161;N,13.376%;IR(KBr) cm^{-1} :3297, 3035, 2996, 2912, 2856, 2728, 2293, 2119, 1902, 1796, 1639, 1595,1567, 1517, 1411, 1510, 1243, 1115, 1059, 908, 847, 819, 786,7 58; 1H NMR: (300MHz, CdCl₃) δ : 7.418-6.855 (m, 13 H); 4.047-3.978 (m, 1H); 1.435-1.377 (m, 2 H) .

2.8. 2-(2-ethylamino-4-chlorophenylaminothiazol-5-oyl)benzothiazole **3f**

This was prepared and purified as per the above mentioned procedure. Yield 70% , m.p. 188-93°C Analysis: Found: C,54.764; H, 3.543; N, 13.453%; Calc. for $C_{19}H_{15}ClN_4OS_2$ (414): C54.994; H, 3.650;N,13.504%;IR(KBr) cm^{-1} :3772, 3292, 3029, 2912, 2885, 2728, 2583, 2293, 1835, 1902, 1639, 1595, 1556, 1517, 1419, 1310, 1238, 1115, 1059, 970, 942, 908, 786, 758, 819; 1H NMR: (300MHz, CdCl₃) δ : 7.400 (d, J= 6.3 Hz , 2 H); 7.362 -7.327 (m, 7 H); 7.270 (d, J= 6.3Hz , 2 H); 7.157 (t, J= 3.3 Hz, 1H); 3.680-3.630 (m, 2 H); 3.365-3.297 (m, 3 H); 1.267-1.231(m, 3 H); 1.195 (t, J= 5.7 Hz, 2 H) ; 1.099 (t, J= 5.4 Hz, 2H).

2.9. 2-(2-propylamino-4-chlorophenylaminothiazol-5-oyl)benzothiazole **3g**

This was prepared and purified as per the above mentioned procedure. Yield 69%, m.p. 223°C Analysis: Found: C, 55.879; H, 4.012; N, 13.012% ; Calc.for $C_{20}H_{17}ClN_4OS_2$ (429): C,55.995;H,4.002;N,13.062%IR(KBr) cm^{-1} :3213, 3174, 3107, 3068, 3018, 2923, 2376, 2114, 1891,1740,1706,1639,1595,1539,1494,1405,1288,1232.1 014,925,825,763,735,679; 1HNMR :(300MHz,CdCl₃) δ : 8.14 (t, J= 11.4 Hz, 1 H) ; 7.993 (d, J= 8.1Hz, 1 H); 7.659 (d, J= 8.1 Hz , 1 H); 7.674-7.509 (m, 3 H) ; 7.487-7.254 (m, 5 H) ; 7.122 (d, J= 8.4 Hz , 1 H) ; 1.393 (d, J= 6.3 Hz, 2 H) ; 1.242-1.167 (m, 4 H) ; 1.095 (d, J= 6.6 Hz , 1 H) ; 0.967-0.850 (m, 1 H) ; FABMS:431(MH⁺).

2.10. 2-(2-isopropylamino-4-chlorophenylaminothiazol-5-oyl)benzothiazole **3h**

This was prepared and purified as per the above mentioned procedure. Yield 68% , m.p. 225°C Analysis: Found: C,55.987; H, 4.002; N, 13.023%; Calc. for $C_{20}H_{17}N_4OS_2$ (429): C,55.995; H, 4.002; N, 13.062%;IR(KBr) cm^{-1} : 3292, 3035, 2912, 2856, 2348, 2293, 2114, 2002, 1946, 1904, 1835, 1639, 1595, 1561, 1517, 1405, 1377, 1310, 1238, 1115,1059, 908, 819,786, 758, 707; 1H NMR: (300MHz, CdCl₃) δ : 8.14 (t, J= 11.4 Hz, 1 H) ; 7.993 (d, J= 8.1Hz, 1 H); 7.659 (d, J= 8.1 Hz , 1 H); 7.674-7.509 (m, 3 H); 7.487-7.254 (m, 5 H) ; 7.122 (d, J= 8.4 Hz , 1 H) ; 1.393 (d, J= 6.3 Hz, 2

H); 1.242-1.167 (m, 4 H); 1.095 (d, J= 6.6 Hz, 1 H); 0.967-0.850 (m, 1 H).

2.11. 2-(2-butylamino-4-chlorophenylaminothiazol-5-oyl)benzothiazole 3i

This was prepared and purified as per the above mentioned procedure. Yield 70%, m.p. 204°C Analysis: Found: C, 56.987; H, 4.002; N, 12.634%; Calc. for C₂₁H₁₉ClN₄OS₂ (443.03): C 56.933; H, 4.331; N, 12.649%; IR(KBr)cm⁻¹: 3426, 3173, 2957, 2867, 1601, 1545, 1488, 1404, 1339, 1313, 1223, 1086, 1006, 822, 718, 676, 629, 644, 693, 688; ¹H NMR: (300MHz, CdCl₂) δ: 7.392-7.348 (m, 2 H); 7.260 (s, 1 H); 7.16 (d, J= 6.3 Hz, 2 H); 3.627-3.578 (m, 2 H); 1.584-1.510 (m, 2 H); 1.369-1.295 (m, 2 H); 0.916 (t, J= 5.4 Hz, 3 H). ¹³C NMR: (75 MHz, DMSO-d₆) δ: 13.672, 20.221, 31.125, 45.489, 76.844, 77.161, 77.479, 126.571, 126.688, 129.757, 130.424, 180.764.

3. Biological evaluation

Antimicrobial activity

The disk diffusion test was performed using standard procedures. The inoculum suspension of each bacterial strain was swabbed on the entire surface of Mueller–Hinton agar plates (MHA, pH 7.3± 0.1, HiMedia). Sterile 6-mm filter paper disks, which were previously impregnated with the compounds.

(3a–i) dissolved in the solvent ethyl acetate, were aseptically placed on MHA surfaces. Sterile paper disks

impregnated with 10% DMSO were used as the negative controls, whereas a disk containing Amikacin was placed in the plate as a positive control. The plates were left at ambient temperature for 15 min to allow excess prediffusion of extracts prior to incubation at 37 °C for 24 h. Diameters of inhibition zones were measured.

The newly synthesised compounds have been screened for antibacterial activity against Gram-negative *Escherichia coli*, *Klebsiella*, *Pseudomonas* and Gram-positive *Bacillus*, *Streptococcus*, *Staphylococcus*. As a reference, Amikacin G is used and a comparison of the data obtained from the study shows that almost all the new compounds now screened appeared to have remarkable antibacterial activity. And the fungal strains of *Candida*, *Aspergillus niger* and *Penicillium*. As a reference, Flucanazole is used and a comparison of the data obtained from the study shows that almost all the new compounds now screened appeared to have remarkable antifungal activity.

4. RESULTS AND DISCUSSIONS

The structures of all compounds were established on the basis of elemental analysis, IR, ¹H NMR, ¹³C NMR and mass spectral data and tested for in vitro antimicrobial activity. The antifungal screening results of these compounds are shown in Table 1 and Table 2 respectively.

Table 1: Zones of inhibition of compounds 3a-i, standard (Amikacin) with different bacterial strains

Compd.	Zone of inhibition (mm)					
	<i>E.coli</i>	<i>Klebsilla</i>	<i>Pseudomonas</i>	<i>Bacillus</i>	<i>Staphylococcus</i>	<i>Streptococcus</i>
3a	10	11	12	11	9	11
3b	8	NA	9	NA	8	8
3c	NA	NA	NA	8	8	NA
3d	NA	7	NA	8	NA	NA
3e	8	NA	NA	NA	NA	NA
3f	13	8	11	13	8	11
3g	9	7	NA	NA	7	8
3h	7	7	NA	NA	NA	NA
3i	8	9	13	14	11	11
Amikacin (Standard)	30	18	22	20	18	20

NA- Not active

Table 2: Zones of inhibition of compounds 3a-i, standard (Flucanazole) with different fungal strains.

Compound	Zone of inhibition (mm)		
	<i>Pencillium</i>	<i>Aspergillus niger</i>	<i>Candida</i>
3a	8	10	9
3b	7	8	7
3c	NA	10	8
3d	NA	NA	8
3e	7	NA	8
3f	8	9	NA
3g	7	NA	8
3h	8	9	NA
3i	10	8	9
Flucanazole (Standard)	14	15	15

NA- Not active

From the above-mentioned results, it may be concluded that the derivatives of benzothiazoles possess moderate to potent antimicrobial activity. Compounds **3a**, **3f** and **3i** were found to be more effective against all bacterial strains and most of the compounds were found to have moderate antifungal activity.

ACKNOWLEDGEMENT

T.F. Abbs Fen Reji thank University Grants Commission, New Delhi for Financial Assistance in the form of Major Research project [F.No.41-229/2012 (SR)]. The authors thank NIIST, Trivandrum and CDRI, Lucknow for spectral and analytical data.

REFERENCES

1. Aiello, S., Wells, G., Stone, E.L., Kadri, H., Bazzi, R., Bell, D.R., Stevens, M.F.G., Mathews, C.S., Bradshaw, T.D., Westwell, A.D., 2008; *J. Med. Chem.* 51: 5135.
2. Delmas, F., Avellaneda, A., Di Giorgio, C.C., Robin, M., De Pierre Timon-David, E., Galy, J.-P., 2004; *Eur. J. Med. Chem.* 39: 685.
3. Gupta, R.R., Ojha, K.G., Kalwania, G.S., Kumar, M., 1980; *Heterocycles* 14: 145.
4. Hunter, R.F., 1925a; *J. Chem. Soc.*, 2023.
5. Hunter, R.F., 1925b; *J. Chem. Soc.*, 2270.
6. Hunter, R.F., 1926; *J. Chem. Soc.*, 1385.
7. Joshua, C.P., Rajasekharan, K.N., 1974; *Chem. Ind.*, 750.
8. Pattan, S.R., Suresh, C.H., Pooja, V.D., 2005; *Indian J. Chem.* 44B: 2404.
9. Sareen, V., Khatri, V., Jain, P., Sharma, K., 2006; *Indian J. Chem.* 45B: 1288.
10. Sawhney, S.N., Singh, J., 1970; *Indian J. Chem.* 8: 882.
11. Ugale, V.G., Patel, H.M., Wadodkar, S.G., Bari, S.B., Shirkhedkar, A.A., Surana, S.S: 2012. *Eur. J. Med. Che.*, 53: 107.
12. Venkatesh, P., Pandeya, S.N., 2009. *Int. J. Chem. Tech. Res.*, 1(4): 1354.
13. Funda, T.; Murat, D.; Seref, D., *Indian J. Chem.*, 2014, 53B, 102.
14. Sathyanarayanmoorthi, V.; Karunathan, R.; Kannappan, V., *J. Chem.*, 2013; ID 258519: 1.
15. Hakan, A.; Oztekin, A., *Int. J. Mol. Sci.*, 2007; 8: 760.
16. Bahl, B. S.; Bhal, A., *Advanced Organic Chemistry*, Ed.4, Springer, 1995; 1117.